Skip to content
DataLookout
Menu

NCT06997497

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 53 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 243 → 247 locations
  2. Minor Study sites: 244 to 245
  3. Minor Study sites: 243 to 244
  4. Minor Trial sites expanded: 239 → 243 locations
  5. Minor Study sites: 238 to 239
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Eligibility criteria expanded, about 17 words
    • Study sites: 236 to 238
    • Interventions: 5-Fluorouracil (Drug), Bevacizumab (Drug), Bevacizumab biosimilar (Drug), Calderasib (Drug), Cetuximab (Biological)… to 5-Fluorouracil (Drug), Bevacizumab (Drug), Bevacizumab biosimilar (Drug), Calderasib (Drug), Cetuximab (Biological)…
    • Secondary endpoints: details revised at 14 of 15 entries
  2. Minor Study sites: 234 to 236v47
  3. Minor Study sites: 232 to 234v46
  1. Minor Trial sites expanded: 228 → 232 locationsv45
  2. Minor Trial sites expanded: 133 → 228 locationsv44
  3. Minor Trial sites reduced: 223 → 133 locationsv43
  4. Minor Trial sites expanded: 220 → 223 locationsv42
  5. Minor Trial sites expanded: 217 → 220 locationsv41
  6. Minor Study sites: 215 to 217v40
  7. Minor Trial sites expanded: 211 → 215 locationsv39
  8. Minor Trial sites expanded: 200 → 211 locationsv38
  9. Minor Trial sites expanded: 196 → 200 locationsv37
  10. Minor Trial sites expanded: 192 → 196 locationsv36
  11. Minor Trial sites expanded: 187 → 192 locationsv35
  12. Minor Trial sites expanded: 180 → 187 locationsv34
  13. Notable Eligibility criteria expanded, about 31 words
    • Trial sites expanded: 161 → 180 locations
    v33
  14. Minor Trial sites expanded: 152 → 161 locationsv32
  15. Minor Trial sites expanded: 148 → 152 locationsv31
  16. Minor Trial sites expanded: 143 → 148 locationsv30
  17. Minor Trial sites expanded: 137 → 143 locationsv29
  18. Minor Trial sites expanded: 133 → 137 locationsv28
  19. Minor Study sites: 124 to 133v27
  20. Minor Study sites: 115 to 124v26
  21. Minor Study sites: 103 to 115v25
  22. Minor Study sites: 100 to 103v24
  23. Minor Study sites: 83 to 100v23
  24. Minor Study sites: 78 to 83v22
  25. Minor Interventions: 5-Fluorouracil (Drug), Bevacizumab (Drug), Bevacizumab biosimilar (Drug), Cetuximab (Biological), Leucovorin/levofolinate calcium (Drug)… to 5-Fluorouracil (Drug), Bevacizumab (Drug), Bevacizumab biosimilar (Drug), Calderasib (Drug), Cetuximab (Biological)…
    • Study title expanded, about 1 word
    v21
  26. Minor Study sites: 74 to 78v20
  27. Minor Study sites: 71 to 74v19
  28. Minor Study sites: 69 to 71v18
  29. Minor Study sites: 68 to 69v17
  30. Minor Primary completion date: Aug 27, 2029 to Mar 28, 2029
    • Interventions: 5-Fluorouracil (Drug), Bevacizumab (Drug), Cetuximab (Biological), Leucovorin/levofolinate calcium (Drug), MK-1084 (Drug), Oxaliplatin… to 5-Fluorouracil (Drug), Bevacizumab (Drug), Bevacizumab biosimilar (Drug), Cetuximab (Biological), Leucovorin/levofolinate calcium (Drug)…
    • Secondary endpoints: details revised at 12 of 15 entries
    v16
  31. Minor Study sites: 65 to 68v15
  32. Minor Study sites: 62 to 65v14
  33. Minor Study sites: 59 to 62v13
  34. Minor Study sites: 52 to 59v12
  35. Minor Study sites: 43 to 52v11
  36. Minor Study sites: 30 to 43v10
  37. Minor Study sites: 23 to 30v9
  38. Minor Study sites: 19 to 23v8
  39. Minor Study sites: 18 to 19v7
  40. Minor Study sites: 8 to 18v6
  41. Minor Study sites: 3 to 8v5
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Timeframe: Up to approximately 28 days
Part 1: Number of Participants Who Experience an Adverse Event (AE)
Timeframe: Up to approximately 44 months
Part 1: Number of Participants Who Discontinue Study Treatment Due to an AE
Timeframe: Up to approximately 44 months
Progression Free Survival (PFS)
Timeframe: Up to approximately 44 months

Secondary (15)

Objective Response Rate (ORR)
Overall Survival (OS)
Duration of Response (DOR)
Part 2: Number of Participants with an Adverse Event (AE)
Part 2: Number of Participants who Discontinue Study Treatment Due to an AE
Show 10 moreShow less
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Change from Baseline in the EORTC-QLQ-C30 Physical Functioning (Items 1-5) Combined Score
Change from Baseline in the EORTC-QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
Change from Baseline in the EORTC-QLQ-C30 Appetite Loss (Item 13) Score
Change from Baseline in the EORTC-Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score
Time to First Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
TTD in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Score
TTD in EORTC QLQ-C30 Appetite Loss (Item 13) Score
TTD in EORTC QLQ-CR29 Bloating (Item 37) Score

Arms and interventions

Calderasib + Cetuximab + mFOLFOX6Experimental

Participants will receive calderasib orally, cetuximab per label every 2 weeks (Q2W), and mFOLFOX6 chemotherapy: oxaliplatin per label every 2 weeks (Q2W), leucovorin or levofolinate calcium per label Q2W, and 5-fluorouracil (5-FU) per label Q2W. Treatment will continue until criteria for discontinuation is met.

mFOLFOX6Active comparator

Participants will receive mFOLFOX6 chemotherapy: oxaliplatin per label Q2W, leucovorin or levofolinate calcium per label Q2W, and 5-fluorouracil (5-FU) per label Q2W. Participants may also receive bevacizumab or bevacizumab biosimilar Q2W at the investigator's discretion. Treatment will continue until criteria for discontinuation is met.

Drugs: Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium, 5-Fluorouracil, Bevacizumab, Bevacizumab biosimilar

Biologicals: Cetuximab

Sites

247 sites in 29 countries

United States 50, China 36, Japan 16, Ukraine 12, France 11, Brazil 10, Chile 10, Spain 9, Italy 8, South Korea 8, Argentina 6, Canada 6, Mexico 6, Turkey (Türkiye) 6, United Kingdom 6, Israel 5, Poland 5, Romania 5, Australia 4, Germany 4, Netherlands 4, Taiwan 4, Colombia 3, Malaysia 3, Philippines 3, Finland 2, Hong Kong 2, Hungary 2, Singapore 1